[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615718":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":57,"collaborators":12,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":12,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":12,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":42,"whyStopped":12,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Chang Gung Memorial Hospital","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"control","NO_INTERVENTION","participants without low-dose oral chemotherapy. Each patient must continue to be tracked for ENE or other postoperative risks for one year, and with blood testing every tree month.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"experimental","EXPERIMENTAL","participants with low-dose oral chemotherapy. Each patient must continue to be tracked for ENE or other postoperative risks for one year, and with blood testing every tree month.",[18],"Procedure: low-dose oral chemotherapy",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"PROCEDURE","low-dose oral chemotherapy","recruit 100 oral cavity cancer patients with ENE or other postoperative risks.10 mL of research blood was drawn four times in total.Each patient must continue to be tracked for ENE or other postoperative risks for one year, and with blood testing every tree month.",[14],[26],{"name":27,"affiliation":28,"role":29},"ChunTa Liao, PhD","Division of Otolaryngology, Chang Gung Memorial Hospital","PRINCIPAL_INVESTIGATOR",[31,35],{"name":27,"role":32,"phone":33,"phoneExt":12,"email":34},"CONTACT","0975360141","liaoct@cgmh.org.tw",{"name":36,"role":32,"phone":37,"phoneExt":12,"email":38},"Chia-Hsun Hsieh, PhD","0975366137","wisdom5000@cgmh.org.tw",[40],{"facility":41,"status":42,"city":43,"state":12,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Linkou Chang Gung Memorial Hospital","RECRUITING","Taoyuan City","333423","Taiwan","TW",{"type":48,"coordinates":49},"Point",[50,51],121.29696,24.99368,{"lat":51,"lon":50},[54,55],{"name":27,"role":32,"phone":33,"phoneExt":12,"email":34},{"name":56,"role":32,"phone":37,"phoneExt":12,"email":38},"ChiaHsun Hsieh, PhD",{"type":29,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"Chun-Ta Liao","Professor Attending Physicians","100615718","circulating-tumor-cell-counts-in-postoperative-ene-positive-oral-cavity-cancer-patients-after-adjuvant-ccrt-100615718",false,"NCT07296250","Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT","A Randomized, Prospective Phase II Clinical Trial - Extended Chemotherapy or Not Based on Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Completing Adjuvant Concurrent Chemoradiotherapy","Inclusion Criteria:\n\nParticipants with Cancer:\n\n1. Aged between 18 and 90 years.\n2. Histologically confirmed diagnosis of head and neck squamous cell carcinoma (HNSCC).\n3. Completed surgical treatment and identified as having high-risk factors, followed by concurrent chemoradiotherapy.\n4. Willing to continue follow-up visits at the hospital after completion of treatment.\n\nExclusion Criteria:\n\n1. Presence of psychiatric disorders.\n2. Deemed unsuitable for participation by the attending physician.\n3. Unwilling to participate in the study.",true,"ALL","18 Months","90 Years",{"count":72,"type":73},100,"ESTIMATED","INTERVENTIONAL",[76],"NA","The aim 1 of this trial is the development of the Circulating tumor cells (CTCs) definition of oral cancer minimal residual disease (MRD), and aim 2 is a prospective trial of oral cancer treatment. If this trial is successful, it is expected that it may be able to provide a standard diagnostic tool (MRD in Oral Cavity Squamous Cell Carcinoma (OCSCC)) and treatment mode (extended adjuvant chemotherapy with low-dose oral chemotherapy). The survival rate of patients will be improved.",[79,80],"Head and Neck Cancer","Oral Cancer",[82,83,84,85,86],"oral cancer","ENE","Circulating tumor cells","Adjuvant concurrent Chemoradiation, adjuvant CCRT","Circulating tumor microemboli (CTM)","2025-12-08",{"date":89,"type":90},"2025-12-22","ACTUAL",{"date":92,"type":90},"2025-08-01",{"date":94,"type":73},"2028-07-31",{"name":5,"class":6},1]